ライフサイエンスコーパス: Met-enkephalin

1 or prodynorphin) with enkephalin (or Phe-Arg-Met-enkephalin).

2 ith morphine, but not opioid peptides (i.e., Met-enkephalin).

3 nosine, serotonin, or methionine enkephalin (met-enkephalin).

4 t-enk-Arg-Phe cleavage preferred (Met-enk is met-enkephalin).

5 ed amounts of nicotine-induced secretion of (Met)enkephalin.

6 neutralizing antibody against the DOR ligand met-enkephalin.

7 the BD simulations for the global motions of met-enkephalin.

8 biological importance, the neurotransmitter met-enkephalin.

9 ay was demonstrated by its cosecretion with [Met]enkephalin.

10 In all neurons tested, methionine (Met)-enkephalin (0.003-30 microm) inhibited the peak amp

11 cordings with patch electrodes, bath-applied met-enkephalin, a nonselective opioid receptor agonist,

12 Thus, amnestic effects of [Leu]- or [Met]enkephalin administration are brain-region specific.

13 y formation produced by [Leu]enkephalin and [Met]enkephalin administration in 2 regions of the 2-day-

14 with localized amnestic effects produced by [Met]enkephalin administration.

15 Previous studies show that Met-enkephalin, an endogenous opioid, down-regulates che

16 ry vesicle cathepsin L in the production of [Met]enkephalin, an endogenous peptide neurotransmitter.

17 The met-enkephalin analog D-Ala2-methionine enkephalinamide

18 nalization, and also enhanced the effects of Met-enkephalin and alpha-neoendorphin, but not endomorph

19 Met-Enkephalin and beta-Endorphin were not affected by d

20 PepE hydrolyzed internal peptide bonds in Met-enkephalin and bradykinin; however, hydrolysis of al

21 ecursor should contain the sequences of both Met-enkephalin and Leu-enkephalin as seen for mammalian

22 The previous detection of Met-enkephalin and Leu-enkephalin in the CNS of the Aust

23 Basal dialysate levels of Met-enkephalin and Leu-enkephalin were 60 +/- 30 and 70

24 Computational studies for met-enkephalin and melittin, employing sequential and pa

25 Accordingly, immunofluorescence for met-enkephalin and neuropeptide tyrosine in these animal

26 Met-enkephalin and substance-P levels declined approxima

27 Here, we report that Leu- and Met-enkephalin and their des-tyrosyl derivatives potentl

28 ssing the D1 subtype were immunopositive for met-enkephalin and vesicular glutamate transporter VGLUT

29 dopin 1 with chromaffin granule components, [Met]enkephalin and a cysteine protease known as "prohorm

30 esses endogenous opioids (beta-endorphin and Met-enkephalin) and uroguanylin in apical compartments c

31 torphin II, [d-Pen(2), d-pen(5)]-enkephalin, met-enkephalin, and SNC-80 ((+)-4-[(alphaR)-alpha-((2S,5

32 nists (DAMGO, fentanyl, methadone, morphine, Met-enkephalin, and SR17018) with and without BMS-986187

33 ntagonists to attenuate the loss of striatal met-enkephalin are consistent with an excitotoxic lesion

34 for serotonin, dopamine-beta-hydroxylase and met-enkephalin are observed in the area and aid in the d

35 imilar to that of DAMGO, alpha-neoendorphin, Met-enkephalin-Arg-Phe, and the putatively endogenous pe

36 ion enhanced u-opioid receptor activation by Met-enkephalin-Arg-Phe, causing a cell type-specific lon

37 s an unconventional enkephalin heptapeptide, Met-enkephalin-Arg-Phe, in the nucleus accumbens of mice

38 Met-enkephalin, as well as morphine, inhibited IL-8-indu

39 oelectrodes for co-detection of dopamine and met-enkephalin at single recording sites in rat striatal

40 Met-enkephalin, but not the mu-selective (DAMGO) and del

41 alized with the secretory vesicle component (Met)enkephalin by confocal immunonfluorescence microscop

42 human SK-N-MC cells results in reduction of (Met)enkephalin by more than 80%, illustrating the promin

43 y 60 min after the last injection to measure met-enkephalin by radioimmunoassay.

44 Production of [Met]enkephalin by cathepsin L occurred by proteolytic pr

45 Training decreased [Met]enkephalin concentration in the LPO but not in the I

46 by orexigenic neuropeptide Y, dynorphin and met-enkephalin, consistent with an anorexic role in ener

47 ) in dorsal horn homogenates and presynaptic met-enkephalin-containing boutons.

48 of the previously studied glycine oligomers; met-enkephalin contains the interesting motions of pheny

49 Met-enkephalin decreased the binding of 125I-Tyr-MIF-1 t

50 dependent secretion of KPI/APP with PTP and (Met)enkephalin demonstrated the colocalization of these

51 Regional activity of endogenous [Met]enkephalin during memory formation is consistent wit

52 y orexigenic neuromodulators neuropeptide Y, met-enkephalin, dynorphin and the catecholamine dopamine

53 Met-enkephalin (ENK) suppressed spontaneous and NMDA-ind

54 L-4Ra, antibodies to opioid peptides such as Met-enkephalin (ENK), B-endorphin and dynorphin A 1-17,

55 bition by gamma-aminobutyric acid (GABA) and met-enkephalin (ENK).

56 onal SK-N-MC cells results in production of (Met)enkephalin from proenkephalin.

57 neuropeptides (neuropeptide Y, substance P, met-enkephalin, galanin, dynorphin A and somatostatin) w

58 either the potency nor the efficacy of D-Ala-Met-enkephalin-Gly-ol (DAMGO) were changed; however, the

59 aining), and within given brain nuclei (more met-enkephalin immunoreactive cells).

60 mouse brains with a decrease in the level of Met-Enkephalin immunoreactivity (ir-Met-Enk) and an accu

61 ss (110 kDa), were colocalized with PTP and (Met)enkephalin in secretory vesicles of adrenal medulla

62 SNL led to increased immunoreactivity for met-enkephalin in dorsal horn homogenates, which was dos

63 Mass spectroscopy confirmed Leu- and Met-enkephalin in skin.

64 ociated with changes in the concentration of met-enkephalin in the brain.

65 Furthermore, labeling for the opioid met-enkephalin in the medial preoptic nucleus (POM) corr

66 dogenous opioids, beta-endorphin and perhaps Met-enkephalin in the thalamus of RLS patients.

67 owed the colocalization of cathepsin L with [Met]enkephalin in secretory vesicles of neuroendocrine c

68 The endogenous opioid met-enkephalin induced monocyte chemotaxis in a pertussi

69 Our data showed that preincubation with Met-enkephalin inhibited both MIP-1 alpha-mediated chemo

70 a(2), N-Me-Phe(4), Gly-ol(5)]-enkephalin and met-enkephalin inhibited both ST-stimulated EPSCs and th

71 Neuropeptides dynorphin and met-enkephalin inhibited dopamine neurons, whereas oxyto

72 These results demonstrate that met-enkephalin inhibition of cholinergic secretion is me

73 O to determine the role of the G proteins in met-enkephalin inhibition of cholinergic stimulation of

74 The SCN did not contain cell bodies with met-enkephalin-IR and substance P-IR, but did contain fi

75 Met-enkephalin is a small opioid peptide comprised of on

76 The dynamics of met-enkephalin is considerably more complicated than tha

77 Met-enkephalin is one of the smallest opiate peptides.

78 dy, which recognized Leu-, Met-, and Phe-Arg-Met-enkephalin, labeled the dorsolateral funiculus and n

79 enkephalin, which did not recognize Leu- and Met-enkephalin, labeled the same puncta.

80 MS2 scans enabled simultaneous monitoring of Met-enkephalin, Leu-enkephalin, and unknown peptides.

81 The method was used to determine met-enkephalin, leu-enkephalin, dynorphin A(1-8), and be

82 rtex and midbrain region and the decrease in met-enkephalin level in the medulla region observed in m

83 by reversing some of the changes induced in met-enkephalin levels in brain by morphine in morphine t

84 ether, midazolam antagonized the increase in met-enkephalin levels in cortex and midbrain region and

85 Met-enkephalin levels in neuronal projections from the e

86 ant animals showed a significant increase in met-enkephalin levels in the cortex (137%) and midbrain

87 ted animals showed a significant decrease in met-enkephalin levels in the pituitary (63%), cortex (39

88 idbrain (89%), and a significant decrease in met-enkephalin levels in the pituitary (74%), cerebellum

89 of midazolam, morphine, and both together on met-enkephalin levels in the rat.

90 drenals (43%), and a significant increase in met-enkephalin levels in the striatum (54%) and pons (51

91 Y 274614 ameliorated the decline in striatal met-enkephalin levels observed in mice after 8 weeks of

92 Hippocampal met-enkephalin levels were reduced to 50% only at 12 wee

93 Finally, in cathepsin L gene knockout mice, [Met]enkephalin levels in brain were reduced significantl

94 YAP3p generated Met-enkephalin-Lys-Lys from amidorphin showing that clea

95 amphetamine (METH) significantly altered the met-enkephalin (M-Enk) systems associated with some, but

96 eurotransmitter (dopamine) and neuropeptide (met-enkephalin, M-ENK) release scaled with stimulation d

97 In contrast, [Met]enkephalin may be amnestic when administered in the

98 , N-MePhe(4), Gly-ol]-enkephalin (DAMGO) and met-enkephalin (ME) inhibited evoked inhibitory postsyna

99 Cs (eIPSCs) was unaffected by perfusion with met-enkephalin (ME) or by mu-, delta-, or kappa-opioid r

100 [Met]Enkephalin (ME), [D-Ser2,Leu5,Thr6]-enkephalin, etor

101 Numerous met-enkephalin (mENK) and dynorphin-immunoreactive bouto

102 Met-enkephalin (mENK), an endogenous opioid, and exogeno

103 vasopressin (AVP), angiotensin II (AII) and met-enkephalin (mENK), and receive input from galanin (G

104 ut was combined with local microinjection of met-enkephalin (Met-ENK) and naltrexone (NLTX) to determ

105 presumed synthesis/enhanced accumulation) of met-enkephalin (Met-Enk) in dorsal and ventral striatum

106 nvestigate the effects of the opioid peptide Met-enkephalin (met-enk) on the release of substance P-l

107 proOpiomelanocortin (POMC), or PVN levels of Met-Enkephalin or beta-Endorphin.

108 de of evoked IPSCs was not altered either by Met-enkephalin or by any of the opioid receptor-selectiv

109 ochemistry for either methionine enkephalin (met-enkephalin) or leucine enkephalin (leu-enkephalin),

110 eine protease cathepsin L for producing the (Met)enkephalin peptide neurotransmitter from proenkephal

111 flux induced by chemokines was unaffected by met-enkephalin pretreatment.

112 lation of enkephalin precursor Penk mRNA and met-enkephalin protein in sensory neurons.

113 subtype regulates MOR function by modulating met-enkephalin release.

114 lted in highly increased cellular levels of (Met)enkephalin, resulting from the conversion of PE to e

115 There are five copies of the Met-enkephalin sequence flanked by sets of paired basic

116 Tyr-MIF-1 (Tyr-Pro-Leu-Gly-NH2) and Met-enkephalin share a saturable transport system (pepti

117 Ketamine enhanced potency and efficacy of Met-enkephalin signaling both in mouse midbrain membrane

118 Our initial study on met-enkephalin strongly suggests that even fairly long t

119 ressing immunoreactivity for calbindin D28k, met-enkephalin, substance P, tyrosine hydroxylase, and p

120 ussis toxin-sensitive G proteins that couple met-enkephalin to the inhibition of cholinergically stim

121 nal nerve ligation is accompanied by D1R and met-enkephalin upregulation, acquired D1LR-mediated anti

122 sensory cells that coexpress beta-endorphin, Met-enkephalin, uroguanylin, and Trpm5 exist in mouse du

123 tch those of mammals (i.e., distributions of met-enkephalin, vasotocin, galanin, calcitonin gene-rela

124 ranslational processing of preproenkephalin, met-enkephalin was more abundant than leu-enkephalin bot

125 lin, and the main olfactory bulb, where only met-enkephalin was observed.

126 All effects of met-enkephalin were mimicked by a mu receptor agonist, b

127 ntrations of endogenous [Leu]enkephalin and [Met]enkephalin were determined for 5 brain regions, and

128 An antibody against Phe-Arg-Met-enkephalin, which did not recognize Leu- and Met-enk

129 These results indicate increased levels of (Met)enkephalin within secretory vesicles of the regulate

130 sites and two C-terminally extended forms of Met-enkephalin: YGGFMRSL and YGGFMGY.